HKEX: 6887
Next Day Disclosure Return
Earlier from Sunshine Lake Pharma Co., Ltd. Class H
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Interim Report 2026
- Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
- Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion